Cholesterol ManagementMay 5, 2026
In the largest trial of Repatha ever run, 27,564 patients took the drug for over two years, and the only side effect that happened more often than with placebo was a slightly sore injection site (2.1% vs 1.6%). That's it. Not muscle pain. Not memory problems. Not new diabetes. One mildly irritated patch of skin in roughly 1 in 50 people.
That mismatch between what worried patients searching online and what the data actually shows is the point of this article. Repatha (evolocumab) has now been studied across more than 60,000 patients in randomized trials and tracked in real-world registries on four continents. The picture is unusually consistent: most people tolerate it, a small minority quit because of it, and the scary stories floating around online aren't backed by the evidence.
Cholesterol ManagementMay 5, 2026
The monthly 420 mg Repatha dose delivered by Pushtronex packed three times the medication of the every-two-week shot into a single application, and it lowered LDL cholesterol by roughly 55 to 75%, the same range as the every-two-week schedule. That equivalence was the whole reason the monthly dosing option existed in the first place.
If you remember Pushtronex, you may have used it. If you have not, here is what it was: a hands-free, on-body delivery system that infused the 420 mg monthly dose of Repatha (evolocumab) over a few minutes once you applied it to your stomach or thigh. Amgen has since shifted Repatha distribution toward the SureClick auto-injector and pre-filled syringe formats, but the underlying monthly dosing option that Pushtronex delivered remains.
The question that matters to anyone searching for this is the same now as it was then: did the monthly schedule actually work, and what should you do if you were on it?
Cardiovascular HealthMay 5, 2026
Triple bypass surgery, a form of coronary artery bypass grafting (CABG) that reroutes blood around three blocked heart arteries, consistently outperforms stents across the outcomes that matter most: survival, heart attacks, and the need for repeat procedures. That advantage holds across large randomized and observational studies, and it becomes more pronounced the longer researchers follow patients, stretching out over 8 to 14 years in high-risk groups.
If you or someone you care about is facing a recommendation for triple bypass, the natural question is whether a less invasive option like stents could do the same job. The research is clear on this, though it comes with nuances worth understanding.
Cardiovascular HealthMay 5, 2026
An abnormal ECG reading can point to something that needs urgent attention, or it can mean almost nothing at all. The difference depends on three things: what kind of abnormality showed up, whether you have symptoms, and what your overall cardiovascular risk looks like. This article walks you through how those pieces fit together so you can have a more informed conversation with your doctor and know when to push for faster follow-up.
Blood TestsMay 5, 2026
A BNP of 100 pg/mL is the number most guidelines flag as clinically significant. But risk doesn't flip on like a switch at 100. In people without heart failure, BNP levels as low as 10 to 29 pg/mL have been linked to roughly 2.5 times higher mortality compared to the lowest values. That means "dangerous" is less about crossing a single line and more about where you sit on a rising slope of risk, shaped by your age, kidney function, weight, and symptoms.
BNP, or B-type natriuretic peptide, is a protein your heart releases when it's under strain. The higher the level, the harder your heart is working. But the number on your lab report doesn't mean the same thing for everyone, and the context you're in (emergency room, routine checkup, ICU) changes interpretation dramatically.
Cardiovascular HealthMay 5, 2026
If you have heart disease and you're already taking a statin, you might wonder whether adding another cholesterol medication could meaningfully protect you from a future heart attack or stroke. Repatha (evolocumab) is one such drug, and we now have some of the longest follow-up data available for any newer cholesterol treatment.
In people with existing heart disease who are already on statins, Repatha cuts LDL cholesterol (the "bad" kind) by about 60% and reduces the risk of major cardiovascular events by 15-20%. The protection appears to grow stronger over time, with up to 8 years of data now showing a 23% lower risk of dying from heart-related causes for those who started the drug earlier. This article will help you understand who benefits most, what the actual numbers mean for individuals, and what we still don't know.
Cardiovascular HealthMay 5, 2026
If you have ever looked at a coronary artery calcium score and wondered whether your number is "good" or "bad," the most honest answer is: it depends on how old you are. A calcium score that would be a red flag at 40 might be completely average at 78. That single number on your report does not carry the same weight across every decade of life, and interpreting it without context can leave you either falsely reassured or unnecessarily anxious.
This article will help you understand what the research says about calcium scores at different ages, why a raw number alone is not enough, and how newer tools can put your result into sharper perspective based on your age, sex, and race.
Cholesterol ManagementMay 5, 2026
In a trial of 27,564 people with established heart disease, Repatha pushed average LDL cholesterol from 92 mg/dL down to 30 mg/dL. That is roughly a 60% drop, achieved on top of statins, sustained for years. The same trial also showed an 18% drop in major cardiovascular events: heart attacks, strokes, and the procedures used to fix them.
Most articles you find about Repatha (evolocumab) are either drug-company brochures or anonymous internet comment threads. The actual reviews you should care about live inside randomized trials and real-world registries that have now followed hundreds of thousands of patient-years on this medication. The picture they paint is consistent: a powerful LDL-lowering injection with a side-effect profile that surprises people for how light it is, paired with hard outcome data that explain why cardiologists keep adding it to high-risk patients despite the price tag.
Cardiovascular HealthMay 5, 2026
Praluent (alirocumab) can cut LDL cholesterol by roughly 60% in patients already taking the highest tolerated statin dose. That alone is striking. But the more compelling finding is what happens next: in a trial of nearly 19,000 people who had recently suffered a heart attack or acute coronary event, that LDL drop translated into a 15% reduction in major cardiovascular events, including heart attack, stroke, and cardiovascular death. The catch is that not everyone gets the same payoff. Where your LDL starts and whether you have diabetes dramatically change the math.
Praluent is a subcutaneous injection, not a pill. It belongs to a class called PCSK9 inhibitors, and it's approved specifically as an add-on for adults with familial hypercholesterolemia or established cardiovascular disease who need more LDL lowering than statins alone can deliver. This isn't a first-line treatment. It's the next step when statins aren't getting the job done.
Weight ManagementMay 5, 2026
If you are starting Repatha and you have heard horror stories about cholesterol medications and weight gain, the trial evidence is reassuring. Across 27,564 patients followed for a median of 2.2 years, Repatha (evolocumab) produced no excess in new-onset diabetes, no shift in glycemic markers, and no overall adverse-event difference compared to placebo. Weight gain is not among the adverse events the trial flagged; the only excess was mild injection-site reactions at 2.1% vs 1.6%.
This matters because the question of "does this cholesterol drug make me gain weight" gets asked about almost every lipid-lowering medication, even though the underlying mechanisms differ completely. Repatha sits in a different drug class than the medications that built that reputation, and its safety profile in trials reflects that difference.
Cardiovascular HealthMay 3, 2026
If you've heard about Leqvio (inclisiran), a new cholesterol drug that only requires two injections a year, you might be wondering: does it actually prevent heart attacks and strokes? The honest answer is that we don't fully know yet. The drug dramatically lowers LDL cholesterol, and that's well-established. But larger trials proving it prevents cardiovascular events are still underway, with key results expected in 2026 and beyond.
Here's what this means for you: Leqvio is genuinely promising based on the science of how it works and early signals from clinical trials. But if you're considering it, you should understand both what we know for sure and what remains unproven.
Cardiovascular HealthMay 2, 2026
Icosapent ethyl (sold as Vascepa) is not your standard fish oil supplement. It's a prescription, purified form of EPA, one specific omega-3 fatty acid, and at 4 grams per day on top of statin therapy, it reduced major cardiovascular events by roughly 25% in high-risk patients. That's a striking number for a drug added to an already-optimized regimen. But the benefit comes with a trade-off that doesn't always make it into the headline: a measurable increase in atrial fibrillation risk.
The story of icosapent ethyl is really a story about residual risk, the cardiovascular danger that persists even after you've gotten your LDL cholesterol under control with a statin. For the right patient, this drug addresses that gap in a way few other add-on therapies have managed.
Cholesterol ManagementMay 2, 2026
Rosuvastatin at just 10 mg lowers LDL cholesterol by roughly 45% on average. That's a significant drop from what's technically classified as a "moderate-intensity" dose, and it puts this single pill in striking distance of higher-dose regimens that come with more side effect concerns. But the story doesn't end at cholesterol numbers. The same research that confirms rosuvastatin's potency also flags real risks around kidney health, diabetes, and genetic vulnerabilities that most people never hear about.
What makes 10 mg a particularly interesting dose is its versatility. It sits at a sweet spot: strong enough to be a workhorse for high-risk patients, low enough to combine with other drugs for even deeper LDL cuts, and capped as the maximum recommended dose for people with advanced kidney disease. Understanding where it shines and where it stumbles matters if you're taking it or considering it.
Cholesterol ManagementApr 30, 2026
A lower dose of a statin paired with ezetimibe can deliver the same cardiovascular protection as cranking the statin dose to maximum, while causing fewer muscle complaints, less diabetes risk, and better long-term adherence. That's the core finding from large randomized trials and meta-analyses comparing these two strategies head to head.
If you've been told you need a statin but worry about tolerability, or if you're already on a high dose and struggling with side effects, this combination approach is worth understanding. The evidence is strong enough that it's reshaping how clinicians think about lipid-lowering therapy, especially for older adults and people prone to statin-related problems.
